Pasar al contenido principal

Non-coding RNAs as novel diagnostic, prognostic and therapeutic biomarkers of cardiovascular disease

IJCI-2016-29393

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 30
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Non-coding RNAs and exercise: pathophysiological role and clinical application in the cardiovascular system

  • Gomes, Clarissa P.C.
  • Gonzalo-Calvo, David de
  • Toro, Rocío
  • Fernandes, Tiago
  • Theisen, Daniel
  • Wang, Da-Zhi
  • Devaux, Yvan
There is overwhelming evidence that regular exercise training is protective against cardiovascular disease (CVD), the main cause of death worldwide. Despite the benefits of exercise, the intricacies of their underlying molecular mechanisms remain largely unknown. Non-coding RNAs (ncRNAs) have been recognized as a major regulatory network governing gene expression in several physiological processes and appeared as pivotal modulators in a myriad of cardiovascular processes under physiological and pathological conditions. However, little is known about ncRNA expression and role in response to exercise. Revealing the molecular components and mechanisms of the link between exercise and health outcomes will catalyse discoveries of new biomarkers and therapeutic targets. Here we review the current understanding of the ncRNA role in exercise-induced adaptations focused on the cardiovascular system and address their potential role in clinical applications for CVD. Finally, considerations and perspectives for future studies will be proposed., National Research Fund [grant number INTER/EUROSTARS/15/10282117 (to C.P.C.G.)]; the Ministerio de Econom´ıa y Competitividad [grant number IJCI-2016-29393 (to D.d.G.C.)]; the CIBER Cardiovascular, which is an Instituto de Salud Carlos III Project [grant number CB16/11/00403 (to D.d.G.C.)]; the Fundacion Publica Andaluza Progreso y Salud para la Financiacion´ de la I+i Biomedica y en Ciencias de las Salud en Andalucia [grant number PI-0011/2014 (to D.d.G.C.)]; the Fundac ´ ¸ ao de Am- ˜ paro a Pesquisa do Estado de S ` ao Paulo (FAPESP) [grant number 2017/04899-9 (to F.P.)]; the NIH grant, U.S.A. [grant numbers ˜ HL085635, HL116919 (to D.-Z.W.)]; the Ministry of Higher Education and Research (to D.T.); the Ministry of Sports of Luxembourg (to D.T.); the National Research Fund [grant number INTER/EUROSTARS/15/10282117 (to Y.D.)]; and the Ministry of Higher Education and Research of Luxembourg (to Y.D.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circulating non-coding RNAs as biomarkers to predict and monitor the response to exercise: chances and hurdles

  • Gonzalo-Calvo, David de
  • Thum, Thomas
We have read the comment by Schmitz and Brand with great interest. We believe that several questions should be answered before accepting non-coding RNAs (ncRNAs) as functional markers in the context of exercise. Contrary to what happens with other cardiovascular therapies,1 the potential of ncRNAs to predict the response to acute exercise and/or training programs remains to be addressed. Previous studies demonstrated that circulating microRNAs (miRNAs) correlate with aerobic performance parameters such as VO2max.2 Specific circulating miRNA profiles have been observed in individuals with different cardiorespiratory fitness levels.3 Therefore, circulating ncRNAs could be useful to monitor cardiovascular health. Nonetheless, whether the baseline ncRNA signature reflects the molecular configuration required for any exercise protocol to exert a preventive and/or therapeutic effect in healthy subjects or cardiovascular patients is unknown. Furthermore, the results in the field of circulating miRNAs and exercise are heterogeneous and hardly comparable due to differences in the experimental designs, characteristics of the participants, and technical approaches.4 Additionally, the translation of ncRNAs to clinical practice is controversial due to relevant methodological limitations.1 This situation might not be linked to the poor performance of ncRNAs as biomarkers but additional efforts are needed, especially in terms of reproducibility., Juan de la Cierva-Incorporacio´n grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393 to D.d.G.-C.); CIBER Cardiovascular (CB16/11/00403 to D.d.G.-C.) is a project of the Instituto de Salud Carlos III; The EU, project HOMAGE, the ERANET-CVD LIPCAR-HF and the DFG (KFO311) to T.T, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circulating microRNAs as emerging cardiac biomarkers responsive to acute exercise

  • Gonzalo-Calvo, David de
  • Dávalos Herrera, Alberto
  • Fernández-Sanjurjo, Manuel
  • Amado-Rodríguez, Laura
  • Díaz-Coto, Susana
  • Tomás-Zapico, Cristina
  • Montero, Ana
  • García-González, Ángela
  • Llorente-Cortés, Vicenta
  • Heras, Maria Eugenia
  • Boraita Pérez, Araceli
  • Díaz-Martínez, Ángel E.
  • Úbeda, Natalia
  • Iglesias-Gutiérrez, Eduardo
[Background] Circulating microRNAs (c-miRNAs) are mediators of intercellular communication with great potential as cardiac biomarkers. The analysis of c-miRNAs in response to physiological stress, such as exercise, would provide valuable information for clinical practice and a deeper understanding of the molecular response to physical activity. Here, we analysed for the first time the acute exercise response of c-miRNAs reported as biomarkers of cardiac disease in a well-characterized cohort of healthy active adults. [Methods] Blood samples were collected immediately before and after (0 h, 24 h, 72 h) a 10-km race, a half-marathon (HM) and a marathon (M). Serum RNA from 10-km and M samples was extracted and a panel of 74 miRNAs analysed using RT-qPCR. c-miRNA response was compared with a panel of nine cardiac biomarkers. Functional enrichment analysis was performed. Pre- and post-M echocardiographic analyses were carried out. [Results]Serum levels of all cardiac biomarkers were upregulated in a dose-dependent manner in response to exercise, even in the absence of symptoms or signs of cardiac injury. A deregulation in the profiles of 5 and 19 c-miRNAs was observed for 10-km and M, respectively. Each race induced a specific qualitative and quantitative alteration of c-miRNAs implicated in cardiac adaptions. Supporting their discriminative potential, a number of c-miRNAs previously associated with cardiac disease were undetectable or stable in response to exercise. Conversely, “pseudo-disease” signatures were also observed. [Conclusions] c-miRNAs may be useful for the management of cardiac conditions in the context of acute aerobic exercise. [Translational aspects of the work] Circulating microRNAs could offer incremental diagnostic value to established and emerging cardiac biomarkers, such as hs-cTnT or NT-proBNP, in those patients with cardiac dysfunction symptoms after an acute bout of endurance exercise. Furthermore, circulating miRNAs could also show “pseudo-disease” signatures in response to acute exercise. Clinical practitioners should be aware of the impact caused by exercise in the interpretation of miRNA data., This work was supported in part by the Ministerio de Economía y Competitividad (DEP2012-39262 and DEP2015-69980-P to EI-G and IJCI-2016-29393 to DdG-C), by the Instituto de Salud Carlos III (FIS, PI11/00315 to AD) and European FEDER Funds, and by the Instituto de Salud Carlos III Sara Borrell Grant (CD14/00109 to DdG-C) and Río Hortega Grant (CM16/00128 to LA-R). CIBER Cardiovascular (CB16/11/00403 to DdG-C and VL-C) and CIBER Enfermedades Respiratorias (CB17/06/00021 to LA-R) are projects of the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy

  • Toro, Rocío
  • Blasco-Turrión, Sara
  • Morales-Ponce, Francisco José
  • González, Pablo
  • Martínez-Camblor, Pablo
  • López-Granados, Amador
  • Brugada, Ramon
  • Campuzano, Oscar
  • Pérez-Serra, Alexandra
  • Rosa Longobardo, Felix
  • Mangas, Alipio
  • Llorente-Cortés, Vicenta
  • Gonzalo-Calvo, David de
Lamin A/C gene (LMNA)-related familial dilated cardiomyopathy (fDCM) is an aggressive heart disease that often leads to transplantation and sudden death. The aim of our study was to evaluate the circulating microRNA (miRNA) profiles of patients with LMNA pathogenic mutations. The study population (N = 75) included (i) patients with pathogenic LMNA mutations responsible for fDCM (LMNAMUT), (ii) age- and sex-matched LMNA wild-type controls (LMNAWT control), and (iii) LMNA wild-type idiopathic DCM (iDCM) patients (LMNAWT iDCM). Detailed clinical information was obtained from each participant. A panel of 179 plasma miRNAs was evaluated using RT-qPCR. An initial screening study was performed in LMNAMUT carriers and age-matched LMNAWT controls (N = 16). Forty-four miRNAs were specifically deregulated in LMNAMUT carriers. Ten miRNA candidates were selected for subsequent validation after coexpression analyses and filtered for expression levels and statistical significance. Among the candidates, let-7a-5p, miR-142-3p, miR-145-5p and miR-454-3p levels were significantly increased in LMNAMUT carriers compared to LMNAWT controls and iDCM patients (P < 0.050). These circulating miRNAs, and their combination, were also associated with the presence of pathogenic mutations in regression and ROC analyses. This signature also discriminates between LMNAWT healthy subjects and LMNAMUT carriers who are phenotypically negative for DCM and between LMNAWT iDCM and LMNA-related DCM patients. Correlation and functional enrichment analyses supported their association with the pathophysiology of the disease. We demonstrated for the first time that a specific miRNA signature could serve as a novel non-invasive tool to assist in the diagnosis of patients with fDCM caused by LMNA pathogenic mutations., This work was supported by the Fundación Pública Andaluza Progreso y Salud para la Financiación de la I+i Biomédica y en Ciencias de las Salud en Andalucia (PI-0011/2014) and a grant in the framework of the Integrated Territorial Initiative (ITI)2014-2020 for the province of Cádiz by the Ministry of Health and the European Regional Developement Fund (ERDF) PI0048-2017 (project co-finantiated 80% by funds from the ERDF operational program of Andalusia 2014-2020) (ITI 0048-2017). This work was also supported by FIS PI14/01729 from the Instituto Salud Carlos III, co-financed by the European Fund for Regional Development (E.F.R.D.), Fundació Marató TV3 (201521 10), and Fundació BLa Caixa.^ CIBER Cardiovascular (CB16/11/00403) is an Instituto de Salud Carlos III Project. DdG-C was a recipient of a Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dilated cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations

  • Domínguez, Fernando
  • Cuenca, Sofía
  • Bilinska, Zofia
  • Toro, Rocío
  • Villard, Eric
  • Barriales-Villa, Roberto
  • Ochoa, Juan Pablo
  • Asselbergs, Folkert
  • Sammani, Arjan
  • Franaszczyk, Maria
  • Akhtar, Muhammad N.
  • Coronado-Albi, Maria José
  • Rangel-Sousa, Diego
  • Rodriguez-Palomares, Jose F.
  • Jiménez-Jáimez, Juan
  • Garcia-Pinilla, José Manuel
  • Ripoll-Vera, Tomás
  • Mogollón-Jiménez, Maria Victoria
  • Fontalba-Romero, Ana
  • Garcia-Medina, Dolores
  • Palomino-Doza, Julian
  • Gonzalo-Calvo, David de
  • Cicerchia, Marcos
  • Salazar-Mendiguchia, Joel
  • Salas, Clara
  • Pankuweit, Sabine
  • Morris Hey, Thomas
  • Mogensen, Jens
  • Barton, Paul J.
  • Charron, Philippe
  • Elliott, Perry
  • García-Pavía, Pablo
[Background] The BAG3 (BLC2-associated athanogene 3) gene codes for an antiapoptotic protein located on the sarcomere Z-disc. Mutations in BAG3 are associated with dilated cardiomyopathy (DCM), but only a small number of cases have been reported to date, and the natural history of BAG3 cardiomyopathy is poorly understood. [Objectives] This study sought to describe the phenotype and prognosis of BAG3 mutations in a large multicenter DCM cohort. [Methods] The study cohort comprised 129 individuals with a BAG3 mutation (62% males, 35.1 ± 15.0 years of age) followed at 18 European centers. Localization of BAG3 in cardiac tissue was analyzed in patients with truncating BAG3 mutations using immunohistochemistry. [Results] At first evaluation, 57.4% of patients had DCM. After a median follow-up of 38 months (interquartile range: 7 to 95 months), 68.4% of patients had DCM and 26.1% who were initially phenotype-negative developed DCM. Disease penetrance in individuals >40 years of age was 80% at last evaluation, and there was a trend towards an earlier onset of DCM in men (age 34.6 ± 13.2 years vs. 40.7 ± 12.2 years; p = 0.053). The incidence of adverse cardiac events (death, left ventricular assist device, heart transplantation, and sustained ventricular arrhythmia) was 5.1% per year among individuals with DCM. Male sex, decreased left ventricular ejection fraction. and increased left ventricular end-diastolic diameter were associated with adverse cardiac events. Myocardial tissue from patients with a BAG3 mutation showed myofibril disarray and a relocation of BAG3 protein in the sarcomeric Z-disc. [Conclusions] DCM caused by mutations in BAG3 is characterized by high penetrance in carriers >40 years of age and a high risk of progressive heart failure. Male sex, decreased left ventricular ejection fraction, and enlarged left ventricular end-diastolic diameter are associated with adverse outcomes in patients with BAG3 mutations., This work was supported by grants from the following institutions: Instituto de Salud Carlos III (ISCIII) (PI14/ 0967, PI15/01551, AC16/0014), CIBERCV (CB16/11/00403), Progreso and Salud Foundation (Junta de Andalucia) (PI-0011/201), Ministry of Economy, Industry and Competitiveness (IJCI-2016-29393), Mutual Medical (Research Award 2017), ERA-CVD Joint Transnational Call 2016 (Genprovic), British Heart Foundation (SP/10/10/28431), Wellcome Trust (107469/Z/15/), NIHR Royal Brompton Cardiovascular Biomedical Research Unit, NIHR Imperial Biomedical Research Center, Health Innovation Challenge Fund award from the Wellcome Trust and Department of Health, U.K. (HICF-R6-373), Danish Heart Foundation (16-R107-A6617), University of Southern Denmark, the Region of Southern Denmark, Odense University Hospital, German Competence Network Heart Failure, (TP9, FKZ 01GI0205), DETECTIN-HF project (ERA-CVD framework), and PROMEX Charitable Foundation. UCL Hospitals NIHR Biomedical Research Center and Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2015-12 eDETECT and CVON2014-40 DOSIS. The CNIC is supported by the Ministry of Economy, Industry and Competitiveness and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). Grants from ISCIII and the Spanish Ministry of Economy and Competitiveness are supported by the Plan Estatal de IþDþI 2013-2016 – European Regional Development Fund (FEDER) “A way of making Europe.” The Hospital Universitario Puerta de Hierro Majadahonda, Hôpital PitiéSalpêtrière, and Saint Bartholomews’ Hospital are members of the European Reference Network for rare, low-prevalence, and complex diseases of the heart (ERN GUARD-Heart). Drs. Ochoa, Cicerchia, and Salazar-Mendiguchia are employees of Health In Code., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study

  • Gonzalo-Calvo, David de
  • Cediel, Germán
  • Bär, Christian
  • Núñez,Julio
  • Revuelta-López, Elena
  • Gavara, Josep
  • Ríos-Navarro, César
  • Llorente-Cortés, Vicenta
  • Bodí, Vicente
  • Thum, Thomas
  • Bayés Genís, Antoni
Reliable noninvasive prognostic biomarkers for left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) are needed. This study aimed to evaluate a panel of circulating microRNAs (miRNAs) as biomarkers of LV remodeling using cardiovascular magnetic resonance (CMR). We prospectively evaluated patients with a first STEMI treated with primary percutaneous coronary intervention who underwent CMR imaging at 1 week and 6 months after STEMI (n = 70). miRNAs were measured using PCR-based technologies in plasma samples collected at admission. The associations between miRNAs and LV diastolic and systolic volumes, and ejection fraction at 6-months were estimated in adjusted models. Median age was 60 years, 71.4% were male. miR-1254 was significantly associated in univariate analyses. Patients in the highest tertile of miR-1254 exhibited lower values of LVEDVI and LVESVI and higher values of LVEF at 1 week. After comprehensive multivariate adjustment including clinical, CMR variables, hs-troponin-T and NT-proBNP, miRNA-1254 was associated with decreasing LVESVI (P = 0.006), and borderline negative associated with LVEDVI (P = 0.063) at 6-months. miR-1254 also exhibited a significant positive association with increasing LVEF during follow-up (P < 0.001). Plasma miRNA-1254 predicted changes in LV volumes and LVEF at 6 months after STEMI. The value of miR-1254 to inform tailored treatment selection and monitor ongoing efficacy deserves further investigation., DdG-C and VLl-C are members of the CardiolincTM network. DdG-C was a recipient of Juan de la CiervaIncorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393). CIBER Cardiovascular is a project of the Instituto de Salud Carlos III. VB was funded by the Instituto de Salud Carlos III and co-funded by FEDER (grant numbers PI17/01836 and PIE15/00013). TT was funded by the EU, project HOMAGE,the ERANET-CVD LIPCAR-HF and by Deutsche Forschungsgemeinschaf (DFG, KFO311). CB received support through Deutsche Forschungsgemeinschaf (BA5631/2-1)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Leukocyte telomere length correlates with hypertrophic cardiomyopathy severity

  • Chatterjee, Shambhabi
  • Gonzalo-Calvo, David de
  • Derda, Anselm A.
  • Schimmel, Katharina
  • Sonnenschein, Kristina
  • Bavendiek, Udo
  • Bauersachs, Johann
  • Bär, Christian
  • Thum, Thomas
Telomere length is a marker of biological aging. Short leukocyte telomere length has been associated with various conditions including cardiovascular disorders. Here, we evaluated if patients with hypertrophic cardiomyopathy have altered leukocyte telomere length and whether this is associated with disease severity. A quantitative polymerase chain reaction-based method was used to measure peripheral blood leukocyte telomere length in 59 healthy control subjects and a well-characterized cohort of 88 patients diagnosed with hypertrophic cardiomyopathy: 32 patients with non-obstructive cardiomyopathy (HNCM) and 56 patients with obstructive cardiomyopathy (HOCM). We observed shorter leukocyte telomeres in both HNCM and HOCM patients compared to healthy controls. Furthermore, leukocyte telomere length was inversely associated with HCM even after adjusting for age and sex. Telomere length of HOCM patients was also inversely correlated with left ventricular outflow tract obstruction. Therefore, HOCM patients were categorized by tertiles of telomere length. Patients in the first tertile (shortest telomeres) had a significantly increased left ventricular posterior wall thickness at end-diastole and higher left ventricular outflow tract gradients, whereas the left ventricular end-diastolic diameter was lower compared with patients in the second and third tertile. In summary, telomere length is associated with the severity of the disease in the HOCM subtype., This work was supported by Deutsche Forschungsgemeinschaft (grant number BA5631/2-1 to CB), the Hannover Medical School REBIRTH Excellence cluster (to TT and JB) and the KFO311 (to TT and JB). DdG-C was recipient of a Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393). CIBER Cardiovascular (CB16/11/00403 to DdG-C) is a project of the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Plasma microRNA profiling reveals novel biomarkers of epicardial adipose tissue: A multidetector computed tomography study

  • Gonzalo-Calvo, David de
  • Vilades, David
  • Martínez-Camblor, Pablo
  • Vea, Ángela
  • Ferrero-Gregori, Andreu
  • Nasarre, Laura
  • Bornachea, Olga
  • Sanchez Vega, J.
  • Leta, Rubén
  • Puig, Núria
  • Benítez, Sonia
  • Sánchez-Quesada, José Luís
  • Carreras, Francesc
  • Llorente-Cortés, Vicenta
Epicardial adipose tissue (EAT) constitutes a novel parameter for cardiometabolic risk assessment and a target for therapy. Here, we evaluated for the first time the plasma microRNA (miRNA) profile as a source of biomarkers for epicardial fat volume (EFV). miRNAs were profiled in plasma samples from 180 patients whose EFV was quantified using multidetector computed tomography. In the screening study, 54 deregulated miRNAs were identified in patients with high EFV levels (highest tertile) compared with matched patients with low EFV levels (lowest tertile). After filtering, 12 miRNAs were selected for subsequent validation. In the validation study, miR-15b-3p, miR-22-3p, miR-148a-3p miR-148b-3p and miR-590-5p were directly associated with EFV, even after adjustment for confounding factors (p value < 0.05 for all models). The addition of miRNA combinations to a model based on clinical variables improved the discrimination (area under the receiver-operating-characteristic curve (AUC) from 0.721 to 0.787). miRNAs correctly reclassified a significant proportion of patients with an integrated discrimination improvement (IDI) index of 0.101 and a net reclassification improvement (NRI) index of 0.650. Decision tree models used miRNA combinations to improve their classification accuracy. These results were reproduced using two proposed clinical cutoffs for epicardial fat burden. Internal validation corroborated the robustness of the models. In conclusion, plasma miRNAs constitute novel biomarkers of epicardial fat burden., D.d.G.-C. was a recipient of a Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393). O.B. (Project 201521-10) and N.P. (Project 201716) were recipients of Fundació Marató TV3. S.B. and J.L.S.-Q. (2017-SGR-1149) and D.d.G.-C., L.N., À.V., D.V., R.L. and V.L.-C. (2017-SGR-946) are members of Quality Research Groups from Generalitat de Catalunya. S.B., J.L.S.-Q., N.P., V.L.-C. and D.d.G.-C. are members of the Group of Vascular Biology of the Spanish Society of Atherosclerosis (SEA). This work was funded by FIS PI14/01729 (to V.L.-C.), FIS PI16/00471 (to J.L.S.-Q.) & FIS PI18/01584 (to V.L.-C.) grants from Instituto Salud Carlos III, co-financed by the European Fund for Regional Development (EFRD) and by Project 201521-10 from Fundació MARATÓ TV3 (to V.L.-C.). CIBERCV (CB16/11/00403 to V.L.-C. and D.d.G.-C. and CB16/11/00276 to A.F.-G.) and CIBERDEM (CB07/08/0016 to J.L.S.-Q.) are projects from Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble low-density lipoprotein receptor-related protein 1 as a biomarker of coronary risk: Predictive capacity and association with clinical events

  • Gonzalo-Calvo, David de
  • Elosua, Roberto
  • Vea, Ángela
  • Subirana, Isaac
  • Sayols, Sergi
  • Marrugat, Jaume
  • Llorente-Cortés, Vicenta
[Background and aims] We aimed to determine whether circulating sLRP1 levels are associated with future coronary events and improve the predictive capacity of the REGICOR (Registre Gironí del Cor) risk function. [Methods] We conducted a case-cohort study based on the follow-up of the REGICOR population-based cohort. Of the 5,404 participants aged between 35 and 74 years, without previous history of cardiovascular disease, 117 subjects with angina or fatal or non-fatal myocardial infarction were included, and 512 individuals were randomly selected as a subcohort (including 14 patients who presented coronary events). sLRP1 levels were measured in basal plasma samples by commercial ELISA. Hazard ratio (HR) was estimated with Cox models adjusted for potential confounding factors. Discrimination and reclassification were analyzed with the c-index and the net reclassification index (NRI), respectively. A Mendelian randomization approach was used to explore the causality of the association between sLRP1 and coronary artery disease (CAD). [Results] The group of participants who presented a CAD event showed higher levels of sLRP1 than the subcohort (2.45 [0.43; 8.31] vs. 2.07 [0.40; 6.65] μg/mL, p < 0.001). sLRP1 was significantly associated with CAD events even after adjustment for confounding factors (adjusted HR per standard deviation = 1.30, 95% CI: 1.01–1.67, p = 0.039). sLRP1 did not increase the predictive capacity or improve cardiovascular risk stratification of the REGICOR function. The LRP1 genetic variants associated with CAD risk were not related to sLRP1 concentration. [Conclusions] Plasma sLRP1 is independently associated with the incidence of coronary events, but it does not improve the predictive capacity of the REGICOR risk function., This work was funded by PERIS from Agència de Gestió d’Ajuts Universitaris i de Recerca [Grant SLT002/16/00088], the Instituto Salud Carlos III, which is co-financed by the European Fund for Regional Development [Grants FIS 94/0540, FIS 99/0013–01, FIS 99/9342, FIS PI020471,FIS PI08/1327, INTRASALUD PI11/01801, CP 06/00100, CES12/025, CP12/03287, ECA07/060, FIS PI14/01729, FIS PI18/01584, RD12/0042/0010/0011/0013/0061], and by the Fundació MARATÓ TV3 [Grant 201521–10; 081630], and the Government of Catalonia through the Agency for Management of University and Research Grants [2009SGR1195, 2014SGR240 and 2017SGR946]. DdG-C was a recipient of a Juan de la Cierva-Incorporación from the Ministerio de Economía y Competitividad [Grant IJCI-2016-29393]. CIBERCV and CIBERESP (CB16/11/00403 to DdG-C and VLl-C; CB16/11/00229 to JM; CB16/11/00246 to RE; CB06/02/0029 to IS) are projects of the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circulating microRNAs in suspected stable coronary artery disease: A coronary computed tomography angiography study, Circulating microRNAs as biomarkers of stable CAD

  • Gonzalo-Calvo, David de
  • Vilades, David
  • Martínez-Camblor, Pablo
  • Vea, Ángela
  • Nasarre, Laura
  • Sanchez Vega, J.
  • Leta, Rubén
  • Carreras, Francesc
  • Llorente-Cortés, Vicenta
Objectives: To explore the diagnostic performance of circulating microRNAs (miRNAs) as biomarkers in patients with suspected stable coronary artery disease (CAD). Methods: Plasma samples were collected from 237 consecutive patients referred for coronary computed tomography angiography (CCTA). Presence, extension and severity of coronary stenosis were evaluated using the indexes: presence of diameter stenosis ≥ 50%, segment involvement score (SIS), segment stenosis score (SSS) and 3-vessel plaque score. A panel of 10 miRNAs previously associated with CAD was analysed using RT-qPCR. Multivariate analyses were used to analyse the associations between biomarkers and indexes. Discrimination was evaluated using the area under the ROC curve (AUC). Decision trees were generated using chi-squared Automatic Interaction Detector (CHAID) prediction models. Results: After comprehensive adjustment including cardiovascular risk factors, medication use, confounding factors and protein-based biomarkers (hs-TnT and hs-CRP), several circulating miRNAs were inversely associated with coronary atherosclerosis extension (SIS and 3-vessel plaque score) and severity (SSS). In the whole population, circulating miRNAs showed a poor discrimination value for all indexes (AUC = 0.539–0.644) and did not increase the discrimination capacity of a clinical model of coronary stenosis presence, extension and severity based on conventional cardiovascular risk factors. Conversely, the inclusion of circulating miRNAs in decision trees produces models that improve the classification of cases and controls in specific patient subgroups. Conclusions: This study identifies a group of circulating miRNAs that failed to improve the discrimination capacity of cardiovascular risk factors but that has the potential to define specific subpopulations of patients with suspected stable CAD., DdG‐C was a recipient of a Juan de la Cierva‐Incorporación grant from the Ministerio de Economía y Competitividad (IJCI‐2016‐29393). This work was funded by FIS PI14/01729 & FIS PI18/01584 grant from Instituto de Salud Carlos III, co‐financed by the European Fund for Regional Development (E.F.R.D.) and by Project 201521‐10 from Fundació MARATÓ TV3. CIBER Cardiovascular (CB16/11/00403 to DdG‐C and VL‐C) is a project from Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circulating miRNAs as mediators in cell-to-cell communication

  • Bär, Christian
  • Thum, Thomas
  • Gonzalo-Calvo, David de
Since their discovery in the blood circulation in 2008 [1], miRNAs have emerged as the subclass of the noncoding RNA superfamily that has gained most attention in biomarker development. Due to their biochemical properties, the number of publications that have explored the clinical application of circulating miRNAs as diagnostic and prognostic indicators of cardiovascular disease has grown exponentially over the last decade [2]. Surprisingly, despite the enormous research and economic interest, the biology of these small noncoding RNAs in circulation is far from being completely understood., This work was supported by Deutsche Forschungsgemeinschaft (Grant Number BA5631/2-1 to C Bär) and KFO311 (to T Thum). D de Gonzalo-Calvo was a recipient of Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393). CIBER Cardiovascular (CB16/11/00403) is an Instituto de Salud Carlos III Project. T Thum has filed and licensed patents in the field of noncoding RNAs. T Thum is founder and holds shares of Cardior Pharmaceuticals GmbH.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: A novel tool for personalized medicine?

  • Gonzalo-Calvo, David de
  • Vea, Ángela
  • Bär, Christian
  • Fiedler, Jan
  • Couch, Liam S.
  • Brotons, Carlos
  • Llorente-Cortés, Vicenta
  • Thum, Thomas
Current clinical guidelines emphasize the unmet need for technological innovations to guide physician decision-making and to transit from conventional care to personalized cardiovascular medicine. Biomarker-guided cardiovascular therapy represents an interesting approach to inform tailored treatment selection and monitor ongoing efficacy. However, results from previous publications cast some doubts about the clinical applicability of biomarkers to direct individualized treatment. In recent years, the non-coding human transcriptome has emerged as a new opportunity for the development of novel therapeutic strategies and biomarker discovery. Non-coding RNA (ncRNA) signatures may provide an accurate molecular fingerprint of patient phenotypes and capture levels of information that could complement traditional markers and established clinical variables. Importantly, ncRNAs have been identified in body fluids and their concentrations change with physiology and pathology, thus representing promising non-invasive biomarkers. Previous publications highlight the translational applicability of circulating ncRNAs for diagnosis and prognostic stratification within cardiology. Numerous independent studies have also evaluated the potential of the circulating non-coding transcriptome to predict and monitor response to cardiovascular treatment. However, this field has not been reviewed in detail. Here, we discuss the state-of-the-art research into circulating ncRNAs, specifically microRNAs and long non-coding RNAs, to support clinical decision-making in cardiovascular therapy. Furthermore, we summarize current methodological and conceptual limitations and propose future steps for their incorporation into personalized cardiology. Despite the lack of robust population-based studies and technical barriers, circulating ncRNAs emerge as a promising tool for biomarker-guided therapy., Sara Borrell grant from the Instituto de Salud Carlos III Grant (CD14/00109) and Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393) to D.d.G.-C.; CIBER Cardiovascular (CB16/11/00403 to D.d.G.-C. and V.L.-C.) is a project of the Instituto de Salud Carlos III; EU, project HOMAGE, the ERANET-CVD LIPCAR-HF, and the DFG (TH903/18-1) to T.T.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Emerging role of microRNAs in dilated cardiomyopathy: evidence regarding etiology

  • Calderón‐Domínguez, María
  • Belmonte, Thalia
  • Quezada-Feijoo, Maribel
  • Ramos-Sánchez, Mónica
  • Fernandez-Armenta, J.
  • Pérez-Navarro, Amparo
  • Cesar, Sergi
  • Peña-Peña, María Luisa
  • Vea, Ángela
  • Llorente-Cortés, Vicenta
  • Mangas, Alipio
  • Gonzalo-Calvo, David de
  • Toro, Rocío
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery disease. This cardiac disorder is a major health problem due to its high prevalence, morbidity, and mortality. DCM is a complex disease with a common phenotype but heterogeneous pathological mechanisms. Early etiological diagnosis and prognosis stratification is crucial for the clinical management of the patient. Advances in imaging technology and genetic tests have provided useful tools for clinical practice. Nevertheless, the assessment of the disease remains challenging. Novel noninvasive indicators are still needed to assist in decision-making. microRNAs (miRNAs), a group of small noncoding RNAs, have been identified as key mediators of cell biology. They are found in a stable form in body fluids and their concentration is altered in response to stress. Previous research has suggested that the miRNA signature constitutes a novel source of noninvasive biomarkers for a wide array of cardiovascular diseases. Specifically, several studies have reported the potential role of miRNAs as clinical indicators among the etiologies of DCM. However, this field has not been reviewed in detail. Here, we summarize the evidence of intracellular and circulating miRNAs in DCM and their usefulness in the development of novel diagnostic, prognostic and therapeutic approaches, with a focus on DCM etiology. Although the findings are still preliminary, due to methodological and technical limitations and the lack of robust population-based studies, miRNAs constitute a promising tool to assist in the clinical management of DCM., This work was co-financed by the by the Ministry of Health of the Junta de Andalucía, within the framework of the “Integrated Territorial Initiative” with file number PI-0048-2017, and under the European Regional Development Fund (ERDF), within the Operational Program of Andalusia ERDF 2014-2020 and funded by the Ministry of Health of the Junta de Andalucía, within the framework of the “grants for the financing of biomedical research, development and innovation in health sciences in Andalusia, for the year 2018” with file number P-0136-2018. DdG-C is a recipient of a Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1 (LRP1)-derived peptides against LDL aggregation

  • Benitez-Amaro, Aleyda
  • Pallara, Chiara
  • Nasarre, Laura
  • Rivas-Urbina,Andrea
  • Benítez, Sonia
  • Vea, Ángela
  • Bornachea, Olga
  • Gonzalo-Calvo, David de
  • Serra-Mir, Gabriel
  • Villegas, Sandra
  • Prades, Roger
  • Sánchez-Quesada, José Luís
  • Chiva, Cristina
  • Sabidó, Eduard
  • Tarragó, Teresa
  • Llorente-Cortés, Vicenta
Aggregated LDL is the first ligand reported to interact with the cluster II CR9 domain of low-density lipoprotein receptor-related protein 1 (LRP1). In particular, the C-terminal half of domain CR9, comprising the region Gly1127-Cys1140 exclusively recognizes aggregated LDL and it is crucial for aggregated LDL binding. Our aim was to study the effect of the sequence Gly1127-Cys1140 (named peptide LP3 and its retro-enantio version, named peptide DP3) on the structural characteristics of sphingomyelinase- (SMase) and phospholipase 2 (PLA2)-modified LDL particles. Turbidimetry, gel filtration chromatography (GFC) and transmission electronic microscopy (TEM) analysis showed that LP3 and DP3 peptides strongly inhibited SMase- and PLA2-induced LDL aggregation. Nondenaturing polyacrylamide gradient gel electrophoresis (GGE), agarose gel electrophoresis and high-performance thin-layer chromatography (HPTLC) indicated that LP3 and DP3 prevented SMase-induced alterations in LDL particle size, electric charge and phospholipid content, respectively, but not those induced by PLA2. Western blot analysis showed that LP3 and DP3 counteracted changes in ApoB-100 conformation induced by the two enzymes. LDL proteomics (LDL trypsin digestion followed by mass spectroscopy) and computational modeling methods evidenced that peptides preserve ApoB-100 conformation due to their electrostatic interactions with a basic region of ApoB-100. These results demonstrate that LRP1-derived peptides are protective against LDL aggregation, even in conditions of extreme lipolysis, through their capacity to bind to ApoB-100 regions critical for ApoB-100 conformational preservation. These results suggests that these LRP1(CR9) derived peptides could be promising tools to prevent LDL aggregation induced by the main proteolytic enzymes acting in the arterial intima., The Ministry of Science and Innovation of Spain, in the framework of the State Plan of Scientific and Technical Innovation Investigation 2013–2016, awarded funding to the project “DEVELOPMENT OF AN INNOVATIVE THERAPY FOR THE TREATMENT OF THE ATHEROSCLEROSIS THROUGH INHIBITION OF CHOLESTEROL VASCULAR ACCUMULATION”, led by IPROTEOS SL with file number RTC-2016-5078-1. This project was also financed by the Ministry of Economy, Industry and Competitiveness (MINECO) in the framework of the Subprogram RETOS-COLABORACIÓN, 2016 call. The project is also co-financed by the European Union with the objective to promoting the technological development, innovation and quality research. Support was also received from SAF2017-89613R (to SV), co-financed by the European Regional Development Fund (ERDF), the Fundació la Marató de TV3 Project 201521-10 (to VLlC), FIS PI13/00364 and PI16/00471 (to JSQ) and FIS PI18/01584 (to VLlC) from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDF. Support was also received from Ministerio de Economía y Competitividad to DdG-C (IJCI-2016-29393). CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/0016 (JSQ) and CIBER de Enfermedades Cardiovasculares (CIBERCV; CB16/1100403 (DdG-C, VLlC) are projects run by the Instituto de Salud Carlos III (ISCIII). The CRG/UPF Proteomics Unit is member of ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We also acknowledge support from the Spanish Ministry of Economy and Competitiveness, “Centro de Excelencia Severo Ochoa 2013–2017”, SEV-2012-0208, and “Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya” (2017SGR595 to ES and 2017SGR946 to VLl-C). SB, JLS-Q, AR-U, DdG-C and VL-C are members of the Group of Vascular Biology of the Spanish Society of Atherosclerosis (SEA).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Altered Brain Metabolome Is Associated with Memory Impairment in the rTg4510 Mouse Model of Tauopathy

  • Tondo, Mireia
  • Wasek, Brandi
  • Escolà-Gil, Joan Carles
  • Gonzalo-Calvo, David de
  • Harmon, Clinton
  • Arning, Erland
  • Bottiglieri, Teodoro
© 2020 by the authors., Alzheimer’s disease (AD) is characterized, amongst other features, by the pathologic accumulation of abnormally phosphorylated tau filaments in neurons that lead to neurofibrillary tangles. However, the molecular mechanisms by which the abnormal processing of tau leads to neurodegeneration and cognitive impairment remain unknown. Metabolomic techniques can comprehensively assess disturbances in metabolic pathways that reflect changes downstream from genomic, transcriptomic and proteomic systems. In the present study, we undertook a targeted metabolomic approach to determine a total of 187 prenominated metabolites in brain cortex tissue from wild type and rTg4510 animals (a mice model of tauopathy), in order to establish the association of metabolic pathways with cognitive impairment. This targeted metabolomic approach revealed significant differences in metabolite concentrations of transgenic mice. Brain glutamine, serotonin and sphingomyelin C18:0 were found to be predictors of memory impairment. These findings provide informative data for future research on AD, since some of them agree with pathological alterations observed in diseased humans., This research was funded by Fundación Alfonso Martín Escudero (2014), Spain (awarded to MT). and a grant from the Juan de la Cierva-Incorporación, Ministerio de Economía y Competitividad (IJCI-2016-29393), Spain (awarded to DdG-C)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy

  • Sonnenschein, Kristina
  • Wilczek, Adriana Luisa
  • Gonzalo-Calvo, David de
  • Pfanne, Angelika
  • Derda, Anselm A.
  • Zwadlo, Carolin
  • Bavendiek, Udo
  • Bauersachs, Johann
  • Fiedler, Jan
  • Thum, Thomas
Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and is associated with a high risk of sudden cardiac death. HCM is characterized by pronounced hypertrophy of cardiomyocytes, fiber disarray and development of fibrosis and can be divided into a non-obstructive (HNCM) and obstructive form (HOCM) therefore requiring personalized therapeutic therapies. In the present study, we investigated the expression patterns of several circulating circular RNAs (circRNAs) as potential biomarkers in patients with HCM. We included 64 patients with HCM and 53 healthy controls to the study and quantitatively measured the expression of a set of circRNAs already known to be associated with cardiac diseases (circDNAJC6) and/or being highly abundant in blood (circTMEM56 and circMBOAT2). Abundancy of circRNAs was then correlated to relevant clinical parameters. Serum expression levels of circRNAs DNAJC6, TMEM56 and MBOAT2 were downregulated in patients with HCM. The inverse association between circRNA levels and HCM remained unchanged even after adjusting for confounding factors. All circRNAs, evaluated separately or in combination, showed a robust discrimination capacity when comparing control subjects with HCM, HNCM or HOCM patients (AUC from 0.722 to 0.949). Two circRNAs, circTMEM56 and circDNAJC6, significantly negatively correlated with echocardiographic parameters for HOCM. Collectively, circulating circRNAs DNAJC6, TMEM56 and MBOAT2 can distinguish between healthy and HCM patients. In addition, circTMEM56 and circDNAJC6 could serve as indicators of disease severity in patients with HOCM. Thus, circRNAs emerge as novel biomarkers for HCM facilitating the clinical decision making in a personalized manner., This work was supported by Junge Akademie, MHH (to K.S.), ERC grant Longheart (to T.T.) and Deutsche Forschungsgemeinschaft, TRR_267 (to T.T.) and KFO311 (to T.T. and J.B. (D.d.G.C. was a recipient of a Juan de la Cierva-Incorporación grant from the Ministry of Science Innovation and Universities (IJCI-2016-29393). CIBER Cardiovascular (CB16/11/00403 to DdG-C) is a project from Carlos III Health Institute.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Association of circulating microRNAs with coronary artery disease and usefulness for reclassification of healthy individuals: the REGICOR study

  • Dégano, Irene R.
  • Camps-Vilaró, Anna
  • Subirana, Isaac
  • García-Mateo, Nadia
  • Cidad, Pilar
  • Muñoz-Aguayo, Daniel
  • Puigdecanet, Eulàlia
  • Nonell, Lara
  • Vila, Joan
  • Crepaldi, Felipe M.
  • Gonzalo-Calvo, David de
  • Llorente-Cortés, Vicenta
  • Pérez-García, María Teresa
  • Elosua, Roberto
  • Fitó, Montserrat
  • Marrugat, Jaume
Risk prediction tools cannot identify most individuals at high coronary artery disease (CAD) risk. Oxidized low-density lipoproteins (oxLDLs) and microRNAs are actively involved in atherosclerosis. Our aim was to examine the association of CAD and oxLDLs-induced microRNAs, and to assess the microRNAs predictive capacity of future CAD events. Human endothelial and vascular smooth muscle cells were treated with oxidized/native low-density lipoproteins, and microRNA expression was analyzed. Differentially expressed and CAD-related miRNAs were examined in serum samples from (1) a case-control study with 476 myocardial infarction (MI) patients and 487 controls, and (2) a case-cohort study with 105 incident CAD cases and 455 randomly-selected cohort participants. MicroRNA expression was analyzed with custom OpenArray plates, log rank tests and Cox regression models. Twenty-one microRNAs, two previously undescribed (hsa-miR-193b-5p and hsa-miR-1229-5p), were up- or down-regulated upon cell treatment with oxLDLs. One of the 21, hsa-miR-122-5p, was also upregulated in MI cases (fold change = 4.85). Of the 28 CAD-related microRNAs tested, 11 were upregulated in MI cases-1 previously undescribed (hsa-miR-16-5p)-, and 1/11 was also associated with CAD incidence (adjusted hazard ratio = 0.55 (0.35–0.88)) and improved CAD risk reclassification, hsa-miR-143-3p. We identified 2 novel microRNAs modulated by oxLDLs in endothelial cells, 1 novel microRNA upregulated in AMI cases compared to controls, and one circulating microRNA that improved CAD risk classification., This work was supported by the Spain’s Ministry of Science and Innovation (Madrid, Spain), co-financed with European Union European Regional Development Funds –ERDF- (FIS-CP12/03287, FIS-14/00449, FIS-PI081327, INTRASALUD PI11/01801, PI15/00064, IJCI-2016-29393 to DdG-C, CIBERCV (CB16/11/00229, 00246, 00403), CIBERESP CB06/02/0029, CIBEROBN CB06/03/0028); the Spain’s ministry of Economy and Competiveness (Madrid, Spain) (BFU2016-75360-R); the BBVA Foundation (Bilbao, Spain) (PR-16-BIO-CAR-0041); the Health Departament of the Generalitat de Catalunya (Barcelona, Spain) through the Agència de Gestió d’Ajuts Universitaris de Recerca de Catalunya (AGAUR) (Barcelona, Spain) (2017SGR222), the Strategic Plan for research and health innovation (PERIS) (Barcelona, Spain) (SLT006/17/00234, SLT002/16/00145, SLT006/17/00029 to IRD); and by the Junta de Castilla y León (Valladolid, Spain) (VA114P17). CIBERs of Pathophysiology of Obesity and Nutrition (CIBEROBN), Cardiovascular Diseases (CIBERCV), and Epidemiology (CIBERESP) are initiatives of the Instituto de Salud Carlos III, Madrid, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Plasma circular RNA hsa_circ_0001445 and coronary artery disease: Performance as a biomarker

  • Vilades, David
  • Martínez-Camblor, Pablo
  • Ferrero-Gregori, Andreu
  • Bär, Christian
  • Lu, Dongchao
  • Xiao, Ke
  • Vea, Ángela
  • Nasarre, Laura
  • Sanchez Vega, J.
  • Leta, Rubén
  • Carreras, Francesc
  • Thum, Thomas
  • Llorente-Cortés, Vicenta
  • Gonzalo-Calvo, David de
The role of circular RNAs (circRNAs) as biomarkers remains poorly characterized. Here, we investigated the performance of the circRNA hsa_circ_0001445 as a biomarker of coronary artery disease (CAD) in a real‐world clinical practice setting. Plasma hsa_circ_0001445 was measured in a study population of 200 consecutive patients with suspected stable CAD who had undergone coronary computed tomographic angiography (CTA). Multivariable logistic models were constructed combining conventional risk factors with established biomarkers and hsa_circ_0001445. Model robustness was internally validated by the bootstrap technique. Biomarker accuracy was evaluated using the C‐index. The integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were also calculated. Risk groups were developed via classification tree models. The stability of plasma hsa_circ_0001445 was evaluated under different clinical conditions. hsa_circ_0001445 levels were associated with higher coronary atherosclerosis extent and severity with a 2‐fold increase across tertiles (28.4%‐50.0%). Levels of hsa_circ_0001445 were proportional to coronary atherosclerotic burden, even after comprehensive adjustment for cardiovascular risk factors, medications, and established biomarkers (fully adjusted OR = 0.432 for hsa_circ_0001445 as a continuous variable and fully adjusted OR = 0.277 for hsa_circ_0001445 as a binary variable). The classification of patients was improved with the incorporation of hsa_circ_0001445 into a base clinical model (CM) composed of conventional cardiovascular risk factors, showing an IDI of 0.047 and NRI of 0.482 for hsa_circ_0001445 as a continuous variable and an IDI of 0.056 and NRI of 0.373 for hsa_circ_0001445 as a binary variable. A trend toward higher discrimination capacity was also observed (C‐indexCM = 0.833, C‐indexCM+continuous hsa_circ_0001445 = 0.856 and C‐indexCM+binary hsa_circ_0001445 = 0.855). Detailed analysis of stability showed that hsa_circ_0001445 was present in plasma in a remarkably stable form. In vitro, hsa_circ_0001445 was downregulated in extracellular vesicles secreted by human coronary smooth muscle cells upon exposure to atherogenic conditions. In patients with suspected stable CAD referred for coronary CTA, plasma hsa_circ_0001445 improves the identification of coronary artery atherosclerosis., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immunization with the Gly1127-Cys1140 amino acid sequence of the LRP1 receptor reduces atherosclerosis in rabbits. Molecular, immunohistochemical and nuclear imaging studies

  • Bornachea, Olga
  • Benitez-Amaro, Aleyda
  • Vea, Ángela
  • Nasarre, Laura
  • Gonzalo-Calvo, David de
  • Escolà-Gil, Joan Carles
  • Cedó, Lídia
  • Iborra, Antoni
  • Martínez-Martínez, Laura
  • Juárez, Cándido
  • Cámara, Juan Antonio
  • Espinet, Carina
  • Borrell-Pages, Maria
  • Badimón Maestro, Lina
  • Castell, Joan
  • Llorente-Cortés, Vicenta
Background: The LRP1 (CR9) domain and, in particular, the sequence Gly1127-Cys1140 (P3) plays a critical role in the binding and internalization of aggregated LDL (agLDL). We aimed to evaluate whether immunization with P3 reduces high-fat diet (HFD)-induced atherosclerosis. Methods: Female New Zealand White (NZW) rabbits were immunized with a primary injection and four reminder doses (R1-R4) of IrP (irrelevant peptide) or P3 conjugated to the carrier. IrP and P3-immunized rabbits were randomly divided into a normal diet group and a HFD-fed group. Anti-P3 antibody levels were determined by ELISA. Lipoprotein profile, circulating and tissue lipids, and vascular pro-inflammatory mediators were determined using standardized methods while atherosclerosis was determined by confocal microscopy studies and non-invasive imaging (PET/CT and Doppler ultrasonography). Studies treating human macrophages (hMΦ) and coronary vascular smooth muscle cells (hcVSMC) with rabbit serums were performed to ascertain the potential impact of anti-P3 Abs on the functionality of these crucial cells. Results: P3 immunization specifically induced the production of anti-P3 antibodies (Abs) and did not alter the lipoprotein profile. HFD strongly induced cholesteryl ester (CE) accumulation in the aorta of both the control and IrP groups, and their serum dose-dependently raised the intracellular CE of hMΦ and hcVSMC, promoting TNFR1 and phospho-NF-kB (p65) overexpression. These HFD pro-inflammatory effects were dramatically decreased in the aorta of P3-immunized rabbits and in hMΦ and hcVSMC exposed to the P3 rabbit serums. Microscopy studies revealed that P3 immunization reduced the percentage of lipids, macrophages, and SMCs in the arterial intima, as well as the atherosclerotic extent and lesion area in the aorta. PET/CT and Doppler ultrasonography studies showed that the average standardized uptake value (SUVmean) of the aorta and the arterial resistance index (ARI) of the carotids were more upregulated by HFD in the control and IrP groups than the P3 group. Conclusions: P3 immunization counteracts HFD-induced fatty streak formation in rabbits. The specific blockade of the LRP1 (CR9) domain with Anti-P3 Abs dramatically reduces HFD-induced intracellular CE loading and harmful coupling to pro-inflammatory signaling in the vasculature., The main support to develop this project was received from Fundació MARATÓ TV3 Project 201521-10 (to VLl-C) and FIS PI18/01584 (to VLl-C), FIS16/00139 (to JCE-G) from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. Support was received from Fundació Marató TV3 (Project 201521-10) for post-doctoral funding to OB and from Ministerio de Economía y Competitividad to DdG-C (IJCI-2016-29393). CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/0016 to JCE-G) and CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/1100403 to DdGC, VLl-C and CB16/11/00411 to LB and MB-P) are projects run by the Instituto de Salud Carlos III (ISCIII). We also acknowledge support from “Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya” [2017SGR946 to VLl-C and 2017SGR1480 to LB]. DdG-C, VL-C and JCE-G are members of the Group of Vascular Biology of the Spanish Society of Atherosclerosis (SEA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of biochemical and hematological parameters in adults with Down syndrome

  • Gonzalo-Calvo, David de
  • Barroeta, Isabel
  • Nan, Madalina Nicoleta
  • Rives, José
  • Garzón, Diana
  • Carmona-Iragui, María
  • Benejam, Bessy
  • Videla, Laura
  • Fernández, Susana
  • Altuna, Miren
  • Valldeneu, Silvia
  • Blesa, Rafael
  • Lleó, Alberto
  • Blanco-Vaca, Francisco
  • Fortea, Juan
  • Tondo, Mireia
Down syndrome (DS) is the most common worldwide cause of intellectual disability of genetic origin and the most common chromosomal disorder affecting live-born infants. In addition to intellectual disability, individuals with DS have other comorbidities and complex medical conditions. The increase in the life expectancy of patients with DS requires expanding the knowledge about their clinical characteristics and related laboratory parameters. Several studies exploring laboratory tests in DS patients exist, but their focus is limited to specific areas of metabolism. Therefore, our main goal was to describe the biochemical and hematological findings in a DS cohort and to compare the values to those of a control population. A total of 248 DS individuals and 84 control subjects were enrolled. DS individuals had a higher frequency of several clinical conditions compared to control individuals and presented with significant differences with respect to the controls in both biochemical and hematological parameters. We found age- and sex-related differences in several of the parameters. A good understanding of the differences in our cohort might be of aid in the clinical follow-up of adults with DS, especially considering that the lifespan of DS individuals may reach 60 years of age in developed countries., This study was supported by the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI18/00164 to FB-V and MT, PI14/01126 and PI17/01019 to JF, PI13/01532 and PI16/01825 to RB, PI18/00335 to MCI and PI14/1561, PI17/01896 to AL), the CIBERNED program (Program 1, Alzheimer’s Disease to Alberto Lleó and SIGNAL study, www.signalstudy.es), and CIBERDEM, partly jointly funded by the Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. This work was also supported by the National Institutes of Health (NIA grants 1R01AG056850-01A1; R21AG056974 and R01AG061566 to JF), Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (SLT002/16/00408 to AL), Fundació La Marató de TV3 (20141210 to JF and 044412 to RB). The Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas partially supported this work. This work was also supported by the Generalitat de Catalunya (SLT006/17/00119 to JF) and a grant from the Fundació Bancaria La Caixa to RB. DdG-C was a recipient of a Juan de la Cierva-Incorporación grant from the Ministry of Science Innovation and Universities (IJCI-2016-29393)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity

  • Benitez-Amaro, Aleyda
  • Revuelta-López, Elena
  • Bornachea, Olga
  • Cedó, Lídia
  • Vea, Ángela
  • Herrero, Laura
  • Roglans, Núria
  • Soler-Botija, Carolina
  • Gonzalo-Calvo, David de
  • Nasarre, Laura
  • Camino-López, Sandra
  • García, Eduardo
  • Mató, Eugènia
  • Blanco-Vaca, Francisco
  • Bayés Genís, Antoni
  • Sebastián, David
  • Laguna, Joan Carles
  • Serra, Dolors
  • Llorente-Cortés, Vicenta
Background Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid metabolism and glucose homeostasis. In the context of dyslipemia, LRP1 is upregulated in the heart. Our aim was to evaluate the impact of cardiomyocyte LRP1 deficiency on high fat diet (HFD)-induced cardiac and metabolic alterations, and to explore the potential mechanisms involved. Methods We used TnT-iCre transgenic mice with thoroughly tested suitability to delete genes exclusively in cardiomyocytes to generate an experimental mouse model with conditional Lrp1 deficiency in cardiomyocytes (TNT-iCre+-LRP1flox/flox). Findings Mice with Lrp1-deficient cardiomyocytes (cm-Lrp1−/−) have a normal cardiac function combined with a favorable metabolic phenotype against HFD-induced glucose intolerance and obesity. Glucose intolerance protection was linked to higher hepatic fatty acid oxidation (FAO), lower liver steatosis and increased whole-body energy expenditure. Proteomic studies of the heart revealed decreased levels of cardiac pro-atrial natriuretic peptide (pro-ANP), which was parallel to higher ANP circulating levels. cm-Lrp1−/− mice showed ANP signaling activation that was linked to increased fatty acid (FA) uptake and increased AMPK/ ACC phosphorylation in the liver. Natriuretic peptide receptor A (NPR-A) antagonist completely abolished ANP signaling and metabolic protection in cm-Lrp1−/− mice. Conclusions These results indicate that an ANP-dependent axis controlled by cardiac LRP1 levels modulates AMPK activity in the liver, energy homeostasis and whole-body metabolism., This work was funded by FIS PI14/01729 and FIS PI18/01584 (to VLl-C), FIS16/00139 (to JCE-G) grants from Instituto Salud Carlos III, co-financed by the European Fund for Regional Development (E.F.R.D.) and by the Ministry of Spain-MINECO (SAF2014-52223-C2-1-R to DS, co-financed by the European Fund for Regional Development (E.F.R.D.). Support was received from Ministerio de Economía y Competitividad to DdG-C (IJCI-2016-29393), Agència de Gestió d'Ajuts Universitaris i de Recerca Grant FI to ERL (FI-DGR 2013/00014), Fundació MARATÓ TV3 Project 201521-10 (to VLl-C) and Project 87/C/2016 to DS. CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/0016 (FBV, JCE-G, LC); CB07/08/0017 (AZ), CIBER Fisiopatología de la Obesidad y la Nutrición (CIBEROBN; CB06/03/0001 (DS, LH); CB06/03/0017 (JCL, NR)) and CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/1100403) (DdG-C, VLl-, CS, ERL and AB-G) are Instituto de Salud Carlos III (ISCIII) projects., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

LRP1-Mediated AggLDL Endocytosis Promotes Cholesteryl Ester Accumulation and Impairs Insulin Response in HL-1 Cells

  • Actis Dato, Virginia
  • Benitez-Amaro, Aleyda
  • Gonzalo-Calvo, David de
  • Vázquez, Maximiliano
  • Bonacci, Gustavo
  • Llorente-Cortés, Vicenta
  • Chiabrando, Gustavo Alberto
The cardiovascular disease (CVD) frequently developed during metabolic syndrome and type-2 diabetes mellitus is associated with increased levels of aggregation-prone small LDL particles. Aggregated LDL (aggLDL) internalization is mediated by low-density lipoprotein receptor-related protein-1 (LRP1) promoting intracellular cholesteryl ester (CE) accumulation. Additionally, LRP1 plays a key function in the regulation of insulin receptor (IR) and glucose transporter type 4 (GLUT4) activities. Nevertheless, the link between LRP1, CE accumulation, and insulin response has not been previously studied in cardiomyocytes. We aimed to identify mechanisms through which aggLDL, by its interaction with LRP1, produce CE accumulation and affects the insulin-induced intracellular signaling and GLUT4 trafficking in HL-1 cells. We demonstrated that LRP1 mediates the endocytosis of aggLDL and promotes CE accumulation in these cells. Moreover, aggLDL reduced the molecular association between IR and LRP1 and impaired insulin-induced intracellular signaling activation. Finally, aggLDL affected GLUT4 translocation to the plasma membrane and the 2-NBDG uptake in insulin-stimulated cells. We conclude that LRP1 is a key regulator of the insulin response, which can be altered by CE accumulation through LRP1-mediated aggLDL endocytosis, This work was funded by Secretaría de Ciencia y Tecnología de la Universidad Nacional de Córdoba (SECyT-UNC) grants 2016 and 2017 (to GAC); Fondo para la Investigación Científica y Tecnológica (FONCyT), Préstamo BID Proyecto de Investigación en Ciencia y Tecnología (PICT) grant 2012-2607 and grant 2015-0807 (to GAC); FISPI18/01584 (to VLl-C) from Instituto Salud Carlos III, co-financed by the European Fund for Regional Development (E.F.R.D.) and by Project 201521-10 from Fundació MARATÓ TV3 (to VLl-C). CIBER Cardiovascular (CB16/11/00403 to VLl-C and DdG-C) is a project from Instituto de Salud Carlos III. VAD and MV are doctoral fellows at CONICET, and GRB and GAC are members of the Research Career of CONICET. DdG-C was a recipient of a Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393). DdG, AB-A are members and VLl-C is the PI of Quality Research Group (2017-SGR-946) from Generalitat de Catalunya. VLl-C an, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sex-related differences of fatty acid-binding protein 4 and leptin levels in atrial fibrillation

  • López-Canoa, J. N.
  • Couselo-Seijas, M.
  • Baluja, Aurora
  • González-Melchor, L.
  • Rozados, A.
  • Llorente-Cortés, Vicenta
  • Gonzalo-Calvo, David de
  • Guerra Ramos, José María
  • Vilades, David
  • Leta, Rubén
  • Martínez-Sande, J. L.
  • García-Seara, F. J.
  • Fernández-López, X. A.
  • González-Juanatey, J. R.
  • Eiras, S.
  • Rodríguez-Mañero, M.
Aims: Adiposity plays a key role in the pathogenesis of atrial fibrillation (AF). Our aim was to study the sex differences in adipokines levels according to AF burden. Methods and results: Two independent cohorts of patients were studied: (i) consecutive patients with AF undergoing catheter ablation (n = 217) and (ii) a control group (n = 105). (i) Adipokines, oxidative stress, indirect autonomic markers, and leucocytes mRNA levels were analysed; (ii) correlation between biomarkers was explored with heatmaps and Kendall correlation coefficients; and (iii) logistic regression and random forest model were used to determine predictors of AF recurrence after ablation. Our results showed that: (i) fatty acid-binding protein 4 (FABP4) and leptin levels were higher in women than in men in both cohorts (P < 0.01). In women, FABP4 levels were higher on AF cohort (20 ± 14 control, 29 ± 18 paroxysmal AF and 31 ± 17 ng/mL persistent AF; P < 0.01). In men, leptin levels were lower on AF cohort (22 ± 15 control, 13 ± 16 paroxysmal AF and 13 ± 11 ng/mL persistent AF; P < 0.01). (ii) In female with paroxysmal AF, there was a lower acetylcholinesterase and higher carbonic anhydrase levels with respect to men (P < 0.05). (iii) Adipokines have an important role on discriminate AF recurrence after ablation. In persistent AF, FABP4 was the best predictor of recurrence after ablation (1.067, 95% confidence interval 1-1.14; P = 0.046). Conclusion: The major finding of the present study is the sex-based differences of FABP4 and leptin levels according to AF burden. These adipokines are associated with oxidative stress, inflammatory and autonomic indirect markers, indicating that they may play a role in AF perpetuation., This study was supported by projects (PI16/01282 and PI18/01584) integrated in the Plan Estatal de I+D+I 2016–2019 and cofounded by ISCIII-Subdirección General de Evaluación y Fomento de la Investigación del Fondo Europeo de Desarrollo Regional (FEDER). J.N.L.-C. and M.R.-M. were a recipient of a Sociedade Galega de Cardioloxía (SOGACAR) research grant. D.d.G.-C. was a recipient of a Juan de la Cierva-Incorporación grant from the Ministry of Science Innovation and Universities (IJCI-2016-29393). CIBER Cardiovascular (CB16/11/00403 to V.Ll.-C. and D.d.G.-C.) is a project from Carlos III Health Institute., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Circular RNAs: a novel tool in cardiovascular biomarker development?

  • Vea, Ángela
  • Llorente-Cortés, Vicenta
  • Gonzalo-Calvo, David de
As we move towards cardiovascular personalised medicine, the development of novel biomarkers to assist in the decision-making process is a hot topic in translational research. In recent years, the non-coding transcriptome has emerged as a novel source of indicators with clinical applications. A vast number of publications have highlighted the potential of different members of this family as biomarkers, especially microRNAs and long non-coding RNAs. Recent advances in RNA sequencing and bioinformatic analysis have drawn attention to another promising class of non-coding RNAs: circular RNAs (circRNAs). CircRNAs are single-stranded and covalently closed RNA molecules that lack free caps or poly(A) tails. Initially discovered in plant viroids as early as the 1970s, circRNAs were originally considered splicing by-products or background noise. Nonetheless, transcriptome-wide analyses have identified and characterised thousands of circRNAs in diverse human cells, with key functions in the regulation of cellular processes. Indeed, various authors have proposed a causative role in a number of pathological conditions, including cardiovascular disease (CVD). Furthermore, circRNAs have the optimal chemical and biological properties to serve as interesting biomarkers. CircRNAs are free of exonuclease-mediated degradation and have a longer half-life than most linear RNAs, and their expression is cell- and developmental stage- and disease-specific. The presence of circRNAs has been demonstrated in clinical specimens, including whole blood, plasma and serum. Here, we review publications that have evaluated the potential of circRNAs as biomarkers for the diagnosis and prediction of cardiovascular conditions, including atherosclerosis, hypertension, aneurysm and the risk of adverse events. In addition, we discuss current methodological limitations and proposed future steps for their application as clinical indicators., D de Gonzalo-Calvo was a recipient of a Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393). CIBER Cardiovascular (CB16/11/00403 to D de Gonzalo-Calvo and V Llorente-Cortes) is a project of the Instituto de Salud Carlos III., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunization with the Gly 1127 -Cys 1140 amino acid sequence of the LRP1 receptor reduces atherosclerosis in rabbits. Molecular, immunohistochemical and nuclear imaging studies

  • Bornachea, Olga
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Nasarre, Laura
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Cedó, Lídia|||0000-0003-4354-3411
  • Iborra Obiols, Antoni|||0000-0002-8984-5151
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Cámara, Juan Antonio|||0000-0001-7494-1127
  • Espinet, Carina|||0000-0001-8580-6617
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Badimon, Lina|||0000-0002-9162-2459
  • Castell-Conesa, Joan|||0000-0002-6449-9731
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background : The LRP1 (CR9) domain and, in particular, the sequence Gly 1127 -Cys 1140 (P3) plays a critical role in the binding and internalization of aggregated LDL (agLDL). We aimed to evaluate whether immunization with P3 reduces high-fat diet (HFD)-induced atherosclerosis. Methods : Female New Zealand White (NZW) rabbits were immunized with a primary injection and four reminder doses (R1-R4) of IrP (irrelevant peptide) or P3 conjugated to the carrier. IrP and P3-immunized rabbits were randomly divided into a normal diet group and a HFD-fed group. Anti-P3 antibody levels were determined by ELISA. Lipoprotein profile, circulating and tissue lipids, and vascular pro-inflammatory mediators were determined using standardized methods while atherosclerosis was determined by confocal microscopy studies and non-invasive imaging (PET/CT and Doppler ultrasonography). Studies treating human macrophages (hMΦ) and coronary vascular smooth muscle cells (hcVSMC) with rabbit serums were performed to ascertain the potential impact of anti-P3 Abs on the functionality of these crucial cells. Results : P3 immunization specifically induced the production of anti-P3 antibodies (Abs) and did not alter the lipoprotein profile. HFD strongly induced cholesteryl ester (CE) accumulation in the aorta of both the control and IrP groups, and their serum dose-dependently raised the intracellular CE of hMΦ and hcVSMC, promoting TNFR1 and phospho-NF-kB (p65) overexpression. These HFD pro-inflammatory effects were dramatically decreased in the aorta of P3-immunized rabbits and in hMΦ and hcVSMC exposed to the P3 rabbit serums. Microscopy studies revealed that P3 immunization reduced the percentage of lipids, macrophages, and SMCs in the arterial intima, as well as the atherosclerotic extent and lesion area in the aorta. PET/CT and Doppler ultrasonography studies showed that the average standardized uptake value (SUV) of the aorta and the arterial resistance index (ARI) of the carotids were more upregulated by HFD in the control and IrP groups than the P3 group. Conclusions : P3 immunization counteracts HFD-induced fatty streak formation in rabbits. The specific blockade of the LRP1 (CR9) domain with Anti-P3 Abs dramatically reduces HFD-induced intracellular CE loading and harmful coupling to pro-inflammatory signaling in the vasculature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma microRNA Profiling Reveals Novel Biomarkers of Epicardial Adipose Tissue, A Multidetector Computed Tomography Study

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Viladés Medel, David|||0000-0002-3638-9703
  • Martínez-Camblor, Pablo|||0000-0001-7845-3905
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Nasarre, Laura
  • Bornachea, Olga
  • Sánchez Vega, Jesús|||0000-0001-7250-8362
  • Leta, Rubén|||0000-0003-4691-381X
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Epicardial adipose tissue (EAT) constitutes a novel parameter for cardiometabolic risk assessment and a target for therapy. Here, we evaluated for the first time the plasma microRNA (miRNA) profile as a source of biomarkers for epicardial fat volume (EFV). miRNAs were profiled in plasma samples from 180 patients whose EFV was quantified using multidetector computed tomography. In the screening study, 54 deregulated miRNAs were identified in patients with high EFV levels (highest tertile) compared with matched patients with low EFV levels (lowest tertile). After filtering, 12 miRNAs were selected for subsequent validation. In the validation study, miR-15b-3p, miR-22-3p, miR-148a-3p miR-148b-3p and miR-590-5p were directly associated with EFV, even after adjustment for confounding factors (p value < 0.05 for all models). The addition of miRNA combinations to a model based on clinical variables improved the discrimination (area under the receiver-operating-characteristic curve (AUC) from 0.721 to 0.787). miRNAs correctly reclassified a significant proportion of patients with an integrated discrimination improvement (IDI) index of 0.101 and a net reclassification improvement (NRI) index of 0.650. Decision tree models used miRNA combinations to improve their classification accuracy. These results were reproduced using two proposed clinical cutoffs for epicardial fat burden. Internal validation corroborated the robustness of the models. In conclusion, plasma miRNAs constitute novel biomarkers of epicardial fat burden.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction, A cardiovascular magnetic resonance study

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Cediel, Germán|||0000-0001-9667-7507
  • Bär, Christian
  • Núñez, Julio|||0000-0003-1672-7119
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Ríos-Navarro, César
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Bodi, Vicente|||0000-0001-6425-5828
  • Thum, Thomas|||0000-0003-4360-1511
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Reliable noninvasive prognostic biomarkers for left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) are needed. This study aimed to evaluate a panel of circulating microRNAs (miRNAs) as biomarkers of LV remodeling using cardiovascular magnetic resonance (CMR). We prospectively evaluated patients with a first STEMI treated with primary percutaneous coronary intervention who underwent CMR imaging at 1 week and 6 months after STEMI (n = 70). miRNAs were measured using PCR-based technologies in plasma samples collected at admission. The associations between miRNAs and LV diastolic and systolic volumes, and ejection fraction at 6-months were estimated in adjusted models. Median age was 60 years, 71.4% were male. miR-1254 was significantly associated in univariate analyses. Patients in the highest tertile of miR-1254 exhibited lower values of LVEDVI and LVESVI and higher values of LVEF at 1 week. After comprehensive multivariate adjustment including clinical, CMR variables, hs-troponin-T and NT-proBNP, miRNA-1254 was associated with decreasing LVESVI (P = 0.006), and borderline negative associated with LVEDVI (P = 0.063) at 6-months. miR-1254 also exhibited a significant positive association with increasing LVEF during follow-up (P < 0.001). Plasma miRNA-1254 predicted changes in LV volumes and LVEF at 6 months after STEMI. The value of miR-1254 to inform tailored treatment selection and monitor ongoing efficacy deserves further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Bornachea, Olga
  • Cedó, Lídia|||0000-0003-4354-3411
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Herrero, Laura|||0000-0003-4244-4673
  • Roglans, Nuria
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Nasarre, Laura
  • Camino-López, Sandra|||0000-0002-2737-4892
  • García, Eduardo
  • Mato, Eugènia|||0000-0001-8121-9335
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sebastian, David
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Serra, Dolors|||0000-0002-4936-4206
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid metabolism and glucose homeostasis. In the context of dyslipemia, LRP1 is upregulated in the heart. Our aim was to evaluate the impact of cardiomyocyte LRP1 deficiency on high fat diet (HFD)-induced cardiac and metabolic alterations, and to explore the potential mechanisms involved. Methods: We used TnT-iCre transgenic mice with thoroughly tested suitability to delete genes exclusively in cardiomyocytes to generate an experimental mouse model with conditional Lrp1 deficiency in cardiomyocytes (TNT-iCre+-LRP1flox/flox). Findings: Mice with Lrp1-deficient cardiomyocytes (cm-Lrp1-/-) have a normal cardiac function combined with a favorable metabolic phenotype against HFD-induced glucose intolerance and obesity. Glucose intolerance protection was linked to higher hepatic fatty acid oxidation (FAO), lower liver steatosis and increased whole-body energy expenditure. Proteomic studies of the heart revealed decreased levels of cardiac pro-atrial natriuretic peptide (pro-ANP), which was parallel to higher ANP circulating levels. cm-Lrp1-/- mice showed ANP signalingactivation that was linked to increased fatty acid (FA) uptake and increased AMPK/ ACC phosphorylation in the liver. Natriuretic peptide receptor A (NPR-A) antagonist completely abolished ANP signaling and metabolic protection in cm-Lrp1-/- mice. Conclusions: These results indicate that an ANP-dependent axis controlled by cardiac LRP1 levels modulates AMPK activity in the liver, energy homeostasis and whole-body metabolism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy

  • Sonnenschein, Kristina
  • Wilczek, Adriana Luisa
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Pfanne, Angelika
  • Derda, Anselm Arthur
  • Zwadlo, Carolin
  • Bavendiek, Udo
  • Bauersachs, Johann|||0000-0002-9341-117X
  • Fiedler, Jan
  • Thum, Thomas|||0000-0003-4360-1511
Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and is associated with a high risk of sudden cardiac death. HCM is characterized by pronounced hypertrophy of cardiomyocytes, fiber disarray and development of fibrosis and can be divided into a non-obstructive (HNCM) and obstructive form (HOCM) therefore requiring personalized therapeutic therapies. In the present study, we investigated the expression patterns of several circulating circular RNAs (circRNAs) as potential biomarkers in patients with HCM. We included 64 patients with HCM and 53 healthy controls to the study and quantitatively measured the expression of a set of circRNAs already known to be associated with cardiac diseases (circDNAJC6) and/or being highly abundant in blood (circTMEM56 and circMBOAT2). Abundancy of circRNAs was then correlated to relevant clinical parameters. Serum expression levels of circRNAs DNAJC6, TMEM56 and MBOAT2 were downregulated in patients with HCM. The inverse association between circRNA levels and HCM remained unchanged even after adjusting for confounding factors. All circRNAs, evaluated separately or in combination, showed a robust discrimination capacity when comparing control subjects with HCM, HNCM or HOCM patients (AUC from 0.722 to 0.949). Two circRNAs, circTMEM56 and circDNAJC6, significantly negatively correlated with echocardiographic parameters for HOCM. Collectively, circulating circRNAs DNAJC6, TMEM56 and MBOAT2 can distinguish between healthy and HCM patients. In addition, circTMEM56 and circDNAJC6 could serve as indicators of disease severity in patients with HOCM. Thus, circRNAs emerge as novel biomarkers for HCM facilitating the clinical decision making in a personalized manner.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Leukocyte telomere length correlates with hypertrophic cardiomyopathy severity

  • Chatterjee, Shambhabi
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Derda, Anselm Arthur
  • Schimmel, Katharina
  • Sonnenschein, Kristina
  • Bavendiek, Udo
  • Bauersachs, Johann|||0000-0002-9341-117X
  • Bär, Christian
  • Thum, Thomas|||0000-0003-4360-1511
Telomere length is a marker of biological aging. Short leukocyte telomere length has been associated with various conditions including cardiovascular disorders. Here, we evaluated if patients with hypertrophic cardiomyopathy have altered leukocyte telomere length and whether this is associated with disease severity. A quantitative polymerase chain reaction-based method was used to measure peripheral blood leukocyte telomere length in 59 healthy control subjects and a well-characterized cohort of 88 patients diagnosed with hypertrophic cardiomyopathy: 32 patients with non-obstructive cardiomyopathy (HNCM) and 56 patients with obstructive cardiomyopathy (HOCM). We observed shorter leukocyte telomeres in both HNCM and HOCM patients compared to healthy controls. Furthermore, leukocyte telomere length was inversely associated with HCM even after adjusting for age and sex. Telomere length of HOCM patients was also inversely correlated with left ventricular outflow tract obstruction. Therefore, HOCM patients were categorized by tertiles of telomere length. Patients in the first tertile (shortest telomeres) had a significantly increased left ventricular posterior wall thickness at end-diastole and higher left ventricular outflow tract gradients, whereas the left ventricular end-diastolic diameter was lower compared with patients in the second and third tertile. In summary, telomere length is associated with the severity of the disease in the HOCM subtype.